Filing acceptance based on phase III data showing giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results